Login to Your Account

Other News To Note

Wednesday, February 16, 2011
Ceregene Inc., of San Diego, reported gene transfer can provide targeted expression of a neurotrophic factor such as neurturin to restore and preserve dying neurons. The research has significance for Parkinson's disease. Ceregene's neurotrophic therapy, CERE-120, is in clinical trials for advanced Parkinson's disease. The results were published in the current issue of Movement Disorders.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription